98%
921
2 minutes
20
Background And Aims: Despite advances in the medical treatment of Crohn's disease [CD], many patients will still need bowel resections and face the subsequent risk of recurrence and re-resection. We describe contemporary re-resection rates and identify disease-modifying factors and risk factors for re-resection.
Methods: We conducted a retrospective, population-based, individual patient-level data cohort study covering 47.4% of the Danish population, including all CD patients who underwent a primary resection between 2010 and 2020.
Results: Among 631 primary resected patients, 24.5% underwent a second resection, and 5.3% a third. Re-resection rates after 1, 5, and 10 years were 12.6%, 22.4%, and 32.2%, respectively. Reasons for additional resections were mainly disease activity [57%] and stoma reversal [40%]. Disease activity-driven re-resection rates after 1, 5, and 10 years were 3.6%, 10.1%, and 14.1%, respectively. Most stoma reversals occurred within 1 year [80%]. The median time to recurrence was 11.0 months. Biologics started within 1 year of the first resection revealed protective effect against re-resection for stenotic and penetrating phenotypes. Prophylactic biologic therapy at primary ileocaecal resection reduced disease recurrence and re-resection risk (hazard ratio [HR] 0.58, 95% confidence interval [CI] [0.34-0.99], p = 0.047). Risk factors for re-resection were location of resected bowel segments at the primary resection, disease location, disease behaviour, smoking, and perianal disease.
Conclusion: Re-resection rates, categorised by disease activity, are lower than those reported in other studies and are closely associated with disease phenotype and localisation. Biologic therapy may be disease-modifying for certain subgroups when initiated within 1 year of resection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ecco-jcc/jjae070 | DOI Listing |
Surg Oncol
September 2025
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Background: The extent of primary hepatectomy for hepatocellular carcinoma (HCC) may influence long-term outcomes, especially at recurrence. We investigated whether initial minor or major hepatectomy impacts retreatment options and survival following recurrence.
Methods: We retrospectively reviewed patients with primary HCC who underwent either initial major or minor hepatectomy.
Urol Oncol
August 2025
Charleston Area Medical Center, Charleston, WV.
Purpose: The objective of this study is to determine residual tumor characteristics for high grade Ta and T1 bladder tumors following transurethral resection of bladder tumor (TURBT) at a facility where initial aggressive resection is standard.
Methods: This is a retrospective review of patients who had multiple TURBTs done by 2 urologic oncologists at a single facility. During a 5-year period from 2018 to 2022 using specific ICD-10 and CPT codes, the institutional electronic health record was used to identify patients requiring repeat resection for high grade Ta and all T1 bladder cancer.
J Hepatocell Carcinoma
July 2025
Department of Medical Imaging and Radiology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
Background: Repeat hepatic resection (re-resection) and radiofrequency ablation (RFA) are both standard treatments for small recurrent hepatocellular carcinoma (HCC) after curative resection. This study compares long-term outcomes of these treatments.
Methods: This retrospective study included patients with recurrent HCC smaller than 3 cm treated with re-resection or RFA from 2001 to 2019 in a tertiary center.
Gallbladder cancer is the most common biliary malignancy frequently diagnosed incidentally on cholecystectomy specimens for presumed benign disease. Once the diagnosis is confirmed on histopathologically, the treatment must be completed by resecting the gallbladder liver bed and regional lymph nodes. The laparoscopic approach seems to be efficient and oncologically safe.
View Article and Find Full Text PDFJ Neurol Surg B Skull Base
June 2025
Department of Neurological Surgery, Loyola University Medical Center, Maywood, Illinois, United States.
While the endoscopic endonasal approach (EEA) has become a well-established surgery for resection of craniopharyngiomas (CP), the utility of this procedure following subtotal resection from open transcranial approach (TCA) surgery has yet to be explored. Here we present a multi-institutional case series of patients who underwent EEA for treatment of recurrent CP originally treated by TCA, demonstrating the viability of this approach as salvage surgery. Retrospective cohort.
View Article and Find Full Text PDF